NAS:AMAG (USA) Also trade in: Germany

AMAG Pharmaceuticals Inc

$ 10.34 -0.44 (-4.08%)
Volume: 756,548 Avg Vol (1m): 589,456
Market Cap $: 349.15 Mil Enterprise Value $: 348.22 Mil
P/E (TTM): 0.00 P/B: 0.58
Earnings Power Value 12.04
Net Current Asset Value -1.1
Tangible Book -0.61
Projected FCF 40.01
Median P/S Value 65.64
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.00
Cash-To-Debt ranked lower than
88.22% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
AMAG: 1
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.29, Med: 10000, Max: 10000
Current: 1
0.29
10000
Equity-to-Asset 0.57
Equity-to-Asset ranked lower than
78.90% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
AMAG: 0.57
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.33, Med: 0.78, Max: 0.99
Current: 0.57
0.33
0.99
Debt-to-Equity 0.43
Debt-to-Equity ranked lower than
83.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
AMAG: 0.43
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.37, Med: 0.94, Max: 1.17
Current: 0.43
0.37
1.17
Debt-to-EBITDA -10.12
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
AMAG: -10.12
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -4.7, Med: 5.24, Max: 114.16
Current: -10.12
-4.7
114.16
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.18
DISTRESS
GREY
SAFE
Beneish M-Score -2.95
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -24.01%
WACC 6.69%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -36.16
Operating Margin ranked higher than
71.97% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
AMAG: -36.16
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -570.13, Med: -11.67, Max: 30.26
Current: -36.16
-570.13
30.26
Net Margin % -30.90
Net Margin ranked higher than
60.23% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
AMAG: -30.9
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -543.43, Med: -16.75, Max: 109.19
Current: -30.9
-543.43
109.19
ROE % -18.60
ROE ranked higher than
59.05% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
AMAG: -18.6
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -52.39, Med: -9.02, Max: 42.96
Current: -18.6
-52.39
42.96
ROA % -9.37
ROA ranked higher than
69.65% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
AMAG: -9.37
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -44.82, Med: -5.33, Max: 16.42
Current: -9.37
-44.82
16.42
ROC (Joel Greenblatt) % -1261.49
ROC (Joel Greenblatt) ranked lower than
61.00% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
AMAG: -1261.49
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1928.22, Med: -488.06, Max: 481.05
Current: -1261.49
-1928.22
481.05
3-Year Total Revenue Growth Rate 4.30
3-Year Revenue Growth Rate ranked higher than
88.94% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
AMAG: 5.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -78.7, Med: 5.4, Max: 278.5
Current: 5.2
-78.7
278.5
3-Year Total EBITDA Growth Rate -16.50
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
AMAG: -15.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A

» AMAG's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AMAG

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:TCRR NAS:ALBO NAS:KALV XTER:FYB NAS:SVRA NAS:ABEO TSX:TH NAS:PHAS XKRX:299660 SZSE:300404 ROCO:6712 NAS:APM SZSE:300049 SZSE:002286 NAS:RIGL XKRX:144510 XKRX:084110 XKRX:102940 TSXV:EMH SZSE:002868
Traded in other countries AMU.Germany
Address 1100 Winter Street, Waltham, MA, USA, 02451
Founded in 1981, AMAG Pharmaceuticals uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging.

Ratios

Current vs industry vs history
PB Ratio 0.58
PB Ratio ranked higher than
88.88% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
AMAG: 0.58
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.56, Med: 1.95, Max: 6.02
Current: 0.58
0.56
6.02
PS Ratio 0.82
PS Ratio ranked higher than
92.15% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
AMAG: 0.82
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.82, Med: 5.23, Max: 505.93
Current: 0.82
0.82
505.93
EV-to-EBIT -2.43
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
AMAG: -2.43
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -787.3, Med: -3.65, Max: 87.5
Current: -2.43
-787.3
87.5
EV-to-EBITDA -13.26
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
AMAG: -13.26
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -180.4, Med: -4.45, Max: 479.9
Current: -13.26
-180.4
479.9
EV-to-Revenue 0.81
EV-to-Revenue ranked higher than
88.85% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
AMAG: 0.81
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.3, Med: 2.9, Max: 435.3
Current: 0.81
0.3
435.3
Current Ratio 2.30
Current Ratio ranked lower than
75.05% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
AMAG: 2.3
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.51, Med: 8.93, Max: 62.43
Current: 2.3
1.51
62.43
Quick Ratio 2.13
Quick Ratio ranked lower than
72.63% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
AMAG: 2.13
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.4, Med: 8.45, Max: 61
Current: 2.13
1.4
61
Days Inventory 62.77
Days Inventory ranked higher than
76.72% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
AMAG: 62.77
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 51.68, Med: 403.83, Max: 1713.48
Current: 62.77
51.68
1713.48
Days Sales Outstanding 70.34
Days Sales Outstanding ranked higher than
52.10% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
AMAG: 70.34
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 27.4, Med: 62.68, Max: 581.14
Current: 70.34
27.4
581.14
Days Payable 46.11
Days Payable ranked lower than
83.02% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
AMAG: 46.11
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 13.96, Med: 85.23, Max: 1957.24
Current: 46.11
13.96
1957.24

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 0.10
3-Year Share Buyback Rate ranked higher than
60.44% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
AMAG: 0.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -28.7, Med: -6.3, Max: 0.7
Current: 0.1
-28.7
0.7

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.26
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
96.89% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
AMAG: 0.26
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.29, Med: 3.71, Max: 96.83
Current: 0.26
0.29
96.83
Price-to-Median-PS-Value 0.16
Price-to-Median-PS-Value ranked higher than
89.38% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
AMAG: 0.16
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.17, Med: 1.89, Max: 277.17
Current: 0.16
0.17
277.17
Earnings Yield (Joel Greenblatt) % -41.15
Earnings Yield (Greenblatt) ranked lower than
70.49% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
AMAG: -41.15
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -458.4, Med: -15.4, Max: 7.5
Current: -41.15
-458.4
7.5

More Statistics

Revenue (TTM) (Mil) $ 432.42
EPS (TTM) $ -3.87
Beta 0.05
Volatility % 49.59
52-Week Range $ 10.08 - 26.1
Shares Outstanding (Mil) 33.77

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y